Caffeine (1,3,7-Trimethylxanthine)

1. Generic or Accepted Substance Name & Classifications

Accepted Name: Caffeine (1,3,7-Trimethylxanthine)
Common Names, Synonyms & Classifications: Caffeine Anhydrous IP; Trimethylxanthine; Guaranine; Methyltheobromine
Section Classification: Group A — Evidence-Supported Sports Nutrition & Ergogenic Aids (PERF-A02)

2. Pharmacological Class

Methylxanthine Central Nervous System Stimulant & Non-Selective Adenosine (A₁ / A₂A) Receptor Antagonist

3. Mechanism of Action

Readily crosses the blood-brain barrier to competitively antagonise central adenosine A₁ and A₂A receptors, preventing adenosine-induced inhibition of dopamine and noradrenaline release. This reduces perceived exertion (RPE), increases central motor unit recruitment, and at higher micromolar concentrations enhances sarcoplasmic reticulum calcium release.

4. Proposed Performance or Endurance Effects (Pharmacological Effect vs Proven Athletic Outcome)

Pharmacological Effect: Central arousal, reduced rating of perceived exertion (RPE), and heightened vigilance. Proven Athletic Performance Benefit: Validated across endurance time trials (2–4% improvement), team-sport intermittent sprints, and sustained cognitive/tactical tasks at evidence-supported nutritional intakes (3–6 mg/kg body weight ~60 minutes pre-exercise). Unsupported Claims: Supratherapeutic doses (>=9 mg/kg) provide no additional ergogenic benefit and frequently impair performance via severe tremor, anxiety, and tachycardia.

5. Quality of Scientific Evidence

Evidence Assessment: High / Level A Consensus (IOC Consensus Statement & ISSN Position Stand — Extensive meta-analytic evidence across aerobic and anaerobic sports)

6. Approved Medical Uses (Where Applicable)

Caffeine Citrate IP (oral/IV) is an NLEM/IP-recognised medicine for apnoea of prematurity in neonates; Caffeine Anhydrous IP is used as an analgesic adjuvant in migraine/headache combinations.

7. Sports-Related Uses, Misuse Patterns & Contamination Risks

Used via coffee, sports gels, chewing gums, or measured tablets. Misuse includes ingesting highly concentrated anhydrous caffeine powders (where a single tablespoon equals ~10,000 mg—a potentially lethal dose) or stacking multiple pre-workout stimulants late in the evening, causing severe sleep-architecture disruption and impaired recovery.

8. Adverse Effects & Serious Safety Risks

Dose-dependent sinus tachycardia, palpitations, anxiety, fine resting tremor, insomnia, gastro-oesophageal reflux, and diuresis at rest. Acute overdose (>1.5–3 g) causes life-threatening ventricular arrhythmias, hypokalaemia, rhabdomyolysis, and seizures.

9. Contraindications & Precautions

Uncontrolled hypertension, tachyarrhythmias (supraventricular tachycardia, atrial fibrillation), severe anxiety/panic disorder, active peptic ulceration, and pregnancy (limit total daily caffeine <200 mg/day).

10. Drug Interactions

Metabolised primarily (>90%) by hepatic CYP1A2. Fluoroquinolones (Ciprofloxacin), Fluvoxamine, and oral contraceptives inhibit CYP1A2 and markedly prolong caffeine half-life; additive sympathomimetic cardiotoxicity with decongestants (Pseudoephedrine) or bronchodilators.

11. Clinical & Laboratory Monitoring Considerations

Monitor resting heart rate, blood pressure, sleep quality, and CYP1A2 genetic/pharmacokinetic sensitivity (slow vs fast metabolisers).

12. Dependence, Misuse or Withdrawal Concerns

Physical tolerance and withdrawal syndrome are well documented: abrupt cessation after habitual intake (>200–300 mg/day) causes throbbing vascular headache, fatigue, irritability, and impaired concentration peaking at 24–48 hours.

13. Regulatory & Legal Status in India (CDSCO / Drugs Rules / NDPS / FSSAI)

Compendial drug in Indian Pharmacopoeia (IP 2022); regulated in beverages and sports nutrition products under FSSAI standards (which cap caffeine content in caffeinated energy drinks at 145–300 ppm and mandate explicit mg/serving labelling and warnings for children/pregnant women).

14. Official WADA Prohibited-List Status

NOT PROHIBITED — Included in the WADA Monitoring Program (in-competition monitoring to detect patterns of misuse in sport, but not currently a prohibited substance; note that NCAA sets a urinary threshold of 15 mcg/mL).

15. Authoritative Source References & Date of Last Verification